While more doses are on the way, the company warned that demand may still outpace supply.
GlaxoSmithKline has ordering limits in place, so a single provider can’t order and maintain a large stock.
This year the company said it plans to ramp up the frequency and volume of doses shipped.
More articles on supply chain:
3 digital health moves the FDA made in 2018
Novartis, VC firms invest $64M in ‘digital therapeutics’ company
BTG Pharmaceuticals tracks snake-bite treatment with blockchain in partnership with OMNY
